Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
NCT03576547 · M.D. Anderson Cancer Center · PHASE1/PHASE2 · terminated · last registry update 2025-05-08 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-27Also stopped (terminated): M.D. Anderson Cancer Center, Ponatinib + Venetoclax (NCT05268003)
- 2025-10-02Also stopped (terminated): Takeda, Ponatinib + Chemotherapy Agents (NCT04501614)
- 2025-10-02Phase 3 first posted: Nanfang Hospital, Southern Medical University, targeted drug (NCT07203352)
- 2025-09-22Results posted on the registry: St. Jude Children's Research Hospital, Venetoclax + Navitoclax (NCT05192889)
- 2025-09-03Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, olverembatinib (NCT07152041)
- 2025-06-12Results posted on the registry: Dana-Farber Cancer Institute, Doxorubicin + Cytarabine (NCT00476190)
- 2025-06-08Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT02420717)
- 2025-03-06Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Randomization + Blinatumomab + chemotherapy + Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone (NCT06860269)
- 2025-03-04Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Venetoclax + Dasatinib (NCT06855810)
- 2025-02-17Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT00390793)
- 2025-01-15Results posted on the registry: Takeda, Ponatinib + Chemotherapy Agents (NCT04501614)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision